NeuroSense Net Debt To E B I T D A from 2010 to 2024
| NRSNW Stock | USD 0.25 0.13 34.21% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter 0.23492899 | Current Value 0.22 | Quarterly Volatility 0.7109036 |
Check NeuroSense Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeuroSense Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 186.9 K, Depreciation And Amortization of 101.8 K or Interest Expense of 379.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NeuroSense financial statements analysis is a perfect complement when working with NeuroSense Therapeutics Valuation or Volatility modules.
NeuroSense | Net Debt To E B I T D A |
Latest NeuroSense Therapeutics' Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of NeuroSense Therapeutics Ltd over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). NeuroSense Therapeutics' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NeuroSense Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
NeuroSense Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | 0.75 | |
| Geometric Mean | 0.59 | |
| Coefficient Of Variation | 94.40 | |
| Mean Deviation | 0.33 | |
| Median | 0.71 | |
| Standard Deviation | 0.71 | |
| Sample Variance | 0.51 | |
| Range | 2.9821 | |
| R-Value | (0) | |
| Mean Square Error | 0.54 | |
| R-Squared | 0.00000627 | |
| Significance | 0.99 | |
| Slope | (0.0004) | |
| Total Sum of Squares | 7.08 |
NeuroSense Net Debt To E B I T D A History
About NeuroSense Therapeutics Financial Statements
NeuroSense Therapeutics investors use historical fundamental indicators, such as NeuroSense Therapeutics' Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NeuroSense Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | 0.23 | 0.22 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.